NeuroVigil’s iBrain™ in TIME’s “Best Inventions of 2025”
iBrain™ - Copyright © 2025 NeuroVigil, Inc. All Rights Reserved. iBrain™ prototype iBrain™ with two quarters - Copyright © 2025...
Brain
Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome
– An analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed continuing improvements in...
Executive Wellness Retreats: Grey Matters International Announces Expansion of Neuroscience-Based Programs
Discover a neuroscience-based path to better mental health and executive well-being with Grey Matters International. Their personalized retreats combine brain...
JOURTHON® Launches Brain Health Softgel
NEW YORK, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Memory lapses, poor concentration, and mental fatigue are no longer just signs...
Alamar Biosciences Launches NULISAqpcr™ BD-pTau217 Assay: A Breakthrough in Non-Invasive, Brain-Specific Biomarker Detection for Alzheimer’s Disease Research
New Blood-Based Assay Delivers Unparalleled Sensitivity and Specificity to enable the next generation of assay development. FREMONT, Calif., Oct. 9,...
Apollo Biowellness, Inc., Merger Update
North Bergen, New Jersey--(Newsfile Corp. - October 9, 2025) - Apollo Biowellness, Inc. (OTCID: KOAN) (the "Company"), is pleased to...
Medtronic BrainSense™ Adaptive Deep Brain Stimulation named a 2025 TIME Best Inventions
TIME Best Inventions honors extraordinary innovations changing lives DUBLIN, Oct. 9, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader...
Can Neuroimaging Save Psychedelic Drug Development? Upcoming Webinar Hosted by Xtalks
In this free webinar, learn how neuroimaging technologies like PET, fMRI and multimodal approaches provide objective insights into brain mechanisms...
Hemostemix Files for Ethics Approval of its Study of Vascular Dementia
Calgary, Alberta--(Newsfile Corp. - October 9, 2025) - Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is...
Hemostemix Files for Ethics Approval of its Study of Vascular Dementia
Calgary, Alberta--(Newsfile Corp. - October 9, 2025) - Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is...
Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson’s Disease and Movement Disorders
– Data demonstrate ATH434 slows disease progression and stabilizes orthostatic hypotension – – New analysis increases overall confidence in the...
Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease
Event to be held October 14th at 4 p.m. ESTBETHESDA, Md., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc....
Axsome Therapeutics Recognizes Mental Illness Awareness Week Along with the National Advocacy Community
NEW YORK, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era...
Dr. Mark Hyman joins ADvantage Therapeutics Advisory Board to further advance Klotho-Based Longevity Programs at Klothea Bio
World-renowned longevity physician to help guide Klothea Bio as it prepares for a Phase 1B clinical trial of its Klotho...
Phantom Neuro CEO Connor Glass to Present during BioFuture™ 2025
Austin-Headquartered Neurotech Maverick Reflects Upon Industry, Company Growth NEW YORK, Oct. 8, 2025 /PRNewswire/ -- Dr. Connor Glass, CEO and Founder...
Luminopia Awarded on TIME’s List of the World’s Top HealthTech Companies 2025
The company was recognized by TIME for reimagining pediatric treatment for lazy eye, the leading cause of vision loss in...
Theranica Brings First-in-Class, Drug-Free Migraine Care to the Forefront at CNS 2025 with Product Theater and New Real-World Evidence
With a dedicated product theater and new real-world evidence posters, Theranica will spotlight how the Nerivio® REN wearable is reshaping...
Sage Growth Partners Announces New Go-to-Market, Messaging and Sales Enablement Partnership with Xealth
Baltimore-based healthcare growth strategy and marketing firm to provide strategic services and recommendations to help define the next generation of digital...
Apollo Biowellness, Inc., Re-Engages GSS Capital
North Bergen, New Jersey--(Newsfile Corp. - October 8, 2025) - Apollo Biowellness, Inc. (OTCID: KOAN) (the "Company"), is pleased to...
Nexalin Technology Announces Additional Positive Clinical Results in Alzheimer’s Disease with Gen-2 SYNC Neurostimulation Device
40-Hz DIFS™ significantly improves cognitive performance and brain connectivity in peer-reviewed clinical trial Results published in Radiology, the flagship journal...